Avicanna Inc. provided consolidated revenue guidance for the fourth quarter, full year 2021 and full year 2022. For the quarter, the company projected record revenue of $1.3 million, representing the fourth consecutive quarter over quarter increase of at least 30%.

The company projected total fiscal 2021 revenue of $3.3 million, representing a 133% growth from $1.5 million in 2020.

For the full year 2022, the company projected $9 million in consolidated revenue from global operations, which is expected to be led by the anticipated sales of approximately 300,000 units of proprietary cannabinoid-based products.